Sanofi SA has announced its acquisition of Vicebio Ltd, a London-based biotechnology firm, to enhance its respiratory vaccines pipeline. The deal involves an upfront payment of $1.15 billion, with potential milestone payments of up to $450 million. This strategic move introduces Vicebio's 'Molecular Clamp' technology, aimed at improving vaccine design, particularly for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). The acquisition aligns with Sanofi's commitment to vaccine innovation, offering a non-mRNA vaccine option and simplifying vaccine storage and distribution. The acquisition is expected to close in the fourth quarter of 2025, pending regulatory approvals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.